Literature DB >> 18230729

Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations.

Ningwu Huang1, Vishal Agrawal, Kathleen M Giacomini, Walter L Miller.   

Abstract

P450 oxidoreductase (POR) is an electron-donating flavoprotein required for the activity of all microsomal cytochrome P450 enzymes. We sequenced 5,655 bp of the POR gene in a representative population of 842 healthy unrelated individuals in four ethnic groups: 218 African Americans, 260 Caucasian Americans, 179 Chinese Americans, and 185 Mexican Americans. One hundred forty SNPs were detected, of which 43 were found in >/=1% of alleles. Twelve SNPs were in the POR promoter region. Fifteen of 32 exonic variations altered the POR amino acid sequence; 13 of these 15 are previously undescribed missense variations. We found eight indels, only one of which was in the coding region. A previously described variant, A503V, was found on 27.9% of all alleles with some ethnic predilection (19.1% in African Americans, 26.4% in Caucasian Americans, 36.7% Chinese Americans, and 31.0% in Mexican Americans). We built cDNA expression vectors for the 13 previously undescribed missense variants, expressed each protein lacking 27 N-terminal residues in Escherichia coli, and assayed the apparent K(m) and V(max) of each in four assays: reduction of cytochrome c, oxidation of NADPH, 17alpha-hydroxylase activity of P450c17, and 17,20 lyase activity of P450c17. The catalytic activities of several missense mutants differed substantially in these assays, indicating that each POR mutant must be assayed separately with each potential target P450 enzyme. The activity of A503V was reduced to a modest but statistically significant degree in all four assays, suggesting that it may play an important role in interindividual variation in drug response.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18230729      PMCID: PMC2234213          DOI: 10.1073/pnas.0711621105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

1.  Characterization of single-nucleotide polymorphisms in coding regions of human genes.

Authors:  M Cargill; D Altshuler; J Ireland; P Sklar; K Ardlie; N Patil; N Shaw; C R Lane; E P Lim; N Kalyanaraman; J Nemesh; L Ziaugra; L Friedland; A Rolfe; J Warrington; R Lipshutz; G Q Daley; E S Lander
Journal:  Nat Genet       Date:  1999-07       Impact factor: 38.330

2.  Recommendations for a nomenclature system for human gene mutations. Nomenclature Working Group.

Authors:  S E Antonarakis
Journal:  Hum Mutat       Date:  1998       Impact factor: 4.878

3.  Biochemical differences between rat and human cytochrome P450c17 support the different steroidogenic needs of these two species.

Authors:  B J Brock; M R Waterman
Journal:  Biochemistry       Date:  1999-02-02       Impact factor: 3.162

4.  Glu-320 and Asp-323 are determinants of the CYP4A1 hydroxylation regiospecificity and resistance to inactivation by 1-aminobenzotriazole.

Authors:  E A Dierks; S C Davis; P R Ortiz de Montellano
Journal:  Biochemistry       Date:  1998-02-17       Impact factor: 3.162

5.  Statistical analysis of DNA polymorphism.

Authors:  F Tajima
Journal:  Jpn J Genet       Date:  1993-12

6.  Three-dimensional structure of NADPH-cytochrome P450 reductase: prototype for FMN- and FAD-containing enzymes.

Authors:  M Wang; D L Roberts; R Paschke; T M Shea; B S Masters; J J Kim
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

7.  Cytochrome P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): cloning of human adrenal and testis cDNAs indicates the same gene is expressed in both tissues.

Authors:  B C Chung; J Picado-Leonard; M Haniu; M Bienkowski; P F Hall; J E Shively; W L Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

8.  Missense mutation serine106----proline causes 17 alpha-hydroxylase deficiency.

Authors:  D Lin; J A Harikrishna; C C Moore; K L Jones; W L Miller
Journal:  J Biol Chem       Date:  1991-08-25       Impact factor: 5.157

9.  Cytochrome b5 augments the 17,20-lyase activity of human P450c17 without direct electron transfer.

Authors:  R J Auchus; T C Lee; W L Miller
Journal:  J Biol Chem       Date:  1998-02-06       Impact factor: 5.157

10.  Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study.

Authors:  Wiebke Arlt; Elizabeth A Walker; Nicole Draper; Hannah E Ivison; Jon P Ride; Fabian Hammer; Susan M Chalder; Maria Borucka-Mankiewicz; Berthold P Hauffa; Ewa M Malunowicz; Paul M Stewart; Cedric H L Shackleton
Journal:  Lancet       Date:  2004-06-26       Impact factor: 79.321

View more
  66 in total

Review 1.  Malformation syndromes caused by disorders of cholesterol synthesis.

Authors:  Forbes D Porter; Gail E Herman
Journal:  J Lipid Res       Date:  2010-10-07       Impact factor: 5.922

2.  Consequences of POR mutations and polymorphisms.

Authors:  Walter L Miller; Vishal Agrawal; Duanpen Sandee; Meng Kian Tee; Ningwu Huang; Ji Ha Choi; Kari Morrissey; Kathleen M Giacomini
Journal:  Mol Cell Endocrinol       Date:  2010-11-09       Impact factor: 4.102

3.  The P450 oxidoreductase (POR) rs2868177 and cytochrome P450 (CYP) 2B6*6 polymorphisms contribute to the interindividual variability in human CYP2B6 activity.

Authors:  Li-Chen Gao; Fang-Qun Liu; Li Yang; Lin Cheng; Hai-Ying Dai; Ran Tao; Shi-Peng Cao; Di Wang; Jie Tang
Journal:  Eur J Clin Pharmacol       Date:  2016-07-20       Impact factor: 2.953

4.  Electron transfer by human wild-type and A287P mutant P450 oxidoreductase assessed by transient kinetics: functional basis of P450 oxidoreductase deficiency.

Authors:  Yi Jin; Mo Chen; Trevor M Penning; Walter L Miller
Journal:  Biochem J       Date:  2015-05-15       Impact factor: 3.857

Review 5.  Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks.

Authors:  Laure Elens; Rachida Bouamar; Nauras Shuker; Dennis A Hesselink; Teun van Gelder; Ron H N van Schaik
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

6.  Pharmacogenetics of post-transplant diabetes mellitus in children with renal transplantation treated with tacrolimus.

Authors:  Pauline Lancia; Tiphaine Adam de Beaumais; Valéry Elie; Florentine Garaix; Marc Fila; François Nobili; Bruno Ranchin; Pascale Testevuide; Tim Ulinski; Wei Zhao; Georges Deschênes; Evelyne Jacqz-Aigrain
Journal:  Pediatr Nephrol       Date:  2018-02-04       Impact factor: 3.714

7.  Associations of cytochrome P450 oxidoreductase genetic polymorphisms with smoking cessation in a Chinese population.

Authors:  Huijie Li; Suyun Li; Qiang Wang; Chongqi Jia
Journal:  Hum Genet       Date:  2016-09-22       Impact factor: 4.132

8.  Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers.

Authors:  Jing-Jing Zhang; Hua Zhang; Xiao-Liang Ding; Sheng Ma; Li-Yan Miao
Journal:  Eur J Clin Pharmacol       Date:  2012-10-25       Impact factor: 2.953

9.  Extraadrenal 21-hydroxylation by CYP2C19 and CYP3A4: effect on 21-hydroxylase deficiency.

Authors:  Larissa G Gomes; Ningwu Huang; Vishal Agrawal; Berenice B Mendonça; Tania A S S Bachega; Walter L Miller
Journal:  J Clin Endocrinol Metab       Date:  2008-10-28       Impact factor: 5.958

10.  Lack of association of the p450 oxidoreductase *28 single nucleotide polymorphism with the lipid-lowering effect of statins in hypercholesterolemic patients.

Authors:  Georgia Ragia; Vana Kolovou; Anna Tavridou; Laure Elens; Alexandros D Tselepis; Moses Elisaf; Ron H N Van Schaik; Genovefa Kolovou; Vangelis G Manolopoulos
Journal:  Mol Diagn Ther       Date:  2014-06       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.